Surgical outcomes and strategy of hypertrophic obstructive cardiomyopathy.
- Author:
Ya-bin ZHU
1
;
S RAJAN
;
V M KURIAN
;
Zhi-yong LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aortic Valve; surgery; transplantation; Cardiac Surgical Procedures; Cardiomyopathy, Hypertrophic; surgery; China; Coronary Artery Bypass; Female; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; methods; Humans; India; Male; Middle Aged; Mitral Valve; pathology; surgery; transplantation; Treatment Outcome
- From: Journal of Zhejiang University. Science. B 2006;7(2):148-153
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo evaluate the surgical clinical results of hypertrophic obstructive cardiomyopathy.
METHODSWe retrospectively collected data on 24 patients who underwent surgical management in the past ten years in two hospitals in China and Madras Medical Mission in India. Myomectomy was carried out on all patients. Among them 3 patients underwent mitral valve replacement; 2 patients underwent mitral valve repair (anterior mitral leaflet plication); 2 patients underwent aortic valve replacement; 1 patient underwent aortic valve repair; 2 patients underwent aortic root replacement; 1 patient underwent Bentall's procedure and 1 patient underwent coronary artery bypass grafting because of a breached muscle bridge.
RESULTSOne patient died of post-operative heart failure. The mean follow-up time was 4.3 years. There was significant improvement in the symptomatic status. Sixteen patients were asymptomatic with good effort tolerance and only four patients had New York heart association (NYHA) Classes I-II due to associated valvular lesions.
CONCLUSIONOur experience proved that symptomatic hypertrophic obstructive cardiomyopathy or non-symptomatic hypertrophic obstructive cardiomyopathy with combined heart disease is indication for surgery as surgical intervention could get better clinical results in this kind of patients compared with other non-surgical method because it beneficially reduces the systolic anterior motion (SAM) of the mitral valve leaflet, which could not be avoided by other non-surgical treatment.